In a large retrospective cohort study including over 1.6 million patients with Type 2 Diabetes, with no prior diagnosis of obesity associated cancers, a significantly reduced risk in 10 out of 13 obesity associated cancers was reported with the use of GLP-1 agonists, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, pancreatic cancer, meningioma, and multiple myeloma17. This evidence concerns the gene GCG and pancreatic neoplasm.